EGFR and non-small cell lung carcinoma: In addition, the introduction of CSF as a new form of liquid biopsy has enabled higher detection rates of specific EGFR mutations in NSCLC brain metastases patients, contributing to remarkable response rates with EGFR-TKI treatment [110].